Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 9INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1Kidney Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 302Carboplatin 230Cisplatin 159Paclitaxel 153Gemcitabine 153Pemetrexed 122Bevacizumab 121Docetaxel 105durvalumab 83Oxaliplatin 82Nivolumab 82Dexamethasone 80atezolizumab 79Fluorouracil 79Cyclophosphamide 79130-nm albumin-bound paclitaxel 74Fulvestrant 72Capecitabine 67Injections 66Cetuximab 64Leucovorin 63Rituximab 57fludarabine 52Lenalidomide 51venetoclax 47Prednisone 45Irinotecan 42enzalutamide 41Letrozole 41tislelizumab 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Blood Component Removal × 90 days × Clear all
NCT04981119 2026-06-02

BASECAMP-1

A2 Biotherapeutics Inc.

Recruiting
200 enrolled
BreastGastrointestinalGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Mesothelioma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡